Holen Sie sich die Stockscreener-App
827.72
1.87%
-15.75
Handel nachbörslich:
827.72
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Re - The National Law Review
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Regeneron stock holds near lofty levels as class action risk emerges - AD HOC NEWS
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
Regeneron stock slips on a $85.2 billion market value - AD HOC NEWS
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Eastern Progress
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Robbins LLP Urges REGN Investors to Contact the Firm Before - GlobeNewswire
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Biotech Stocks To Watch TodaySeptember 4th - MarketBeat
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire
Regeneron stock trades lower as insider sales and lawsuit weigh on sentiment - AD HOC NEWS
Beyond the genome: Regeneron’s Abecasis on scaling drug discovery with genetic data - biocentury.com
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron stock steadies after strong Q2 figures and pipeline focus - AD HOC NEWS
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact SueWallSt - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 - Morningstar
Regeneron Pharmaceuticals stock hits 52-week high at $847.60 By Investing.com - Investing.com Nigeria
Regeneron Pharmaceuticals stock hits 52-week high at $847.60 - Investing.com
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB - Yahoo Finance
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector? - Barchart.com
Why Did Regeneron Pharmaceuticals (REGN) Climb After Its Latest Update? - simplywall.st
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire
Regeneron stock gains after steady 2026 growth and legal action reminder - AD HOC NEWS
Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
REGN 2-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
Regeneron stock draws investor interest as class action lawsuit and strong earnings frame the outloo - AD HOC NEWS
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (REGN) - The National Law Review
Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View - finance.yahoo.com
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP - finance.yahoo.com
Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline - PR Newswire
Regeneron Pharmaceuticals Inc Initiates Recall of Libtayo (Cemiplimab-Rwlc) Injection, 350 Mg/7 Ml (50 Mg/Ml) For Intravenous Infusion After Dilution, Single-Dose Vial - marketscreener.com
REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials - Yahoo Finance
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - PR Newswire
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron: Why I Still See Upside After The Rally (NASDAQ:REGN) - Seeking Alpha
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Exploring Growth Potential with a Robust Pipeline and Strategic Alliances - DirectorsTalk Interviews
Levi & Korsinsky Reminds Regeneron Pharmaceuticals - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In? - simplywall.st
Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026 - ACCESS Newswire
Why Is Regeneron (NASDAQ:REGN) Drawing Attention After Market Drop? - Kalkine Media
Wealthfront Advisers LLC Invests $4.37 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock holds above $826 as FDA approval and lawsuit reshape risk picture - Ad-hoc-news.de
Tocqueville Asset Management L.P. Acquires Shares of 3,315 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Madison Asset Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ceredex Value Advisors LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. Notice of September 14, 2026 Application Deadline for Class Action LawsuitContact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline - TMX Newsfile
Regeneron Pharmaceuticals (NASDAQ:REGN) Enters New Healthcare Focus - Kalkine Media
Regeneron stock jumps on FDA approval for ultra-rare bone disorder drug - Ad-hoc-news.de
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class ActionContact SueWallSt - Morningstar
Advanz Looks To Nix Regeneron, Bayer Eye Med Patents - Law360
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For The First Adult FOP Treatment - simplywall.st
1.93%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):